在帕金森病中,血陶变化与认知功能障碍之间的关联的探索性分析
Xu Liu1,2,3, Xuanjing Liu3, Yuning Liu1,3
1Department of Neurology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
CNS neuroscience & therapeutics
|October 20, 2024
概括
帕金森病 (PD) 患者的血陶含量升高,与认知能力下降相关. 特定的胺比率显示为PD与认知功能障碍 (PD-CD) 的诊断生物标志物具有前途.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 代谢学 代谢学 代谢学
背景情况:
- 脂代谢与帕金森病 (PD) 的病原发生有关.
- 认知功能障碍是PD患者显著的并发症.
研究的目的:
- 为了研究血陶胺水平与PD患者认知功能障碍之间的关联.
- 为了确定与认知功能障碍 (PD-CD) 相关的PD潜在的血陶生物标志物.
主要方法:
- 血陶化物水平 (Cer 16:0,Cer 18:0,Cer 24:0,Cer 24:1) 通过使用HPLC-MS/MS量化.
- 分析了两个队列:中国东部 (n=290) 和帕金森氏症进展标记者倡议 (PPMI,n=429).
- 评估认知状态,将PD患者分为正常认知 (PD-NC),轻度认知障碍 (PD-MCI) 和痴呆症 (PDD).
主要成果:
- 与健康对照组 (HC) 相比,在PD和MSA组中观察到高血水平的特定陶化物 (Cer 18:0,Cer 24:1) 和陶化物比率 (Cer 16:0/Cer 24:0,Cer 18:0/Cer 24:0,Cer 24:1/Cer 240).
- 在PD-NC,PD-MCI和PDD组中发现了胺比率的显著差异,PDD显示最高水平.
- 在PD患者的5年随访期间,较高的基线血陶化物水平预测了加速认知衰退.
- 一个Cer 18:0/Cer 24:0和Cer 24:1/Cer 24:0的生物标记面板有效地区分了PD-CD和PD-NC.
结论:
- 血陶含量,特别是特定的比率,与帕金森病的认知功能障碍有关.
- 这些发现表明,血陶具有作为PD-CD的诊断生物标志物的潜力.
- 进一步的研究可能会验证这些胺在治疗PD认知障碍的临床使用.
相关概念视频
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:15Parkinson's Disease: Overview
486
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
486
01:30Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
101
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
101